Status:
COMPLETED
Denosumab Sequential Therapy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Osteoporosis
Eligibility:
All Genders
50-80 years
Phase:
PHASE4
Brief Summary
Denosumab is a potent anti-resorptive agent and is now widely used in the treatment of osteoporosis. Although denosumab has excellent effect to increase bone mass and prevent fracture in FREEDOM study...
Detailed Description
Denosumab is a monoclonal antibody directed against the protein RANK-L, the principal regulator of osteoclast development. Thus, it acts as a potent anti-resorptive agent and is now widely used in the...
Eligibility Criteria
Inclusion
- Postmenopausal women
- Men \>50-year-old
- After Denosumab treatment ≥ 2 years due to osteoporosis
Exclusion
- Patientshadeverusedantiosteoporosismedications other than Dmab
- Estimated glomerular filtration rate \<35 ml/min.
- Malignancy
- Continuous steroid treatment, hormone therapy or other medical treatment affecting bone metabolism
- Secondary osteoporosis
- Metabolic bone diseases
- Contraindications to ZOL
- Patients older than 80 years old
- Hypocalcemia
Key Trial Info
Start Date :
April 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT03868033
Start Date
April 12 2019
End Date
December 31 2023
Last Update
April 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Orthopedics, National Taiwan University Hospital
Taipei, N/A = Not Applicable, Taiwan, 64041